Nilutamida Lafedar
Nilutamida Lafedar Uses, Dosage, Side Effects, Food Interaction and all others data.
Nilutamida Lafedar is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Nilutamida Lafedar is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Nilutamida Lafedar blocks the action of androgens of adrenal and testicular origin that stimulate the growth of normal and malignant prostatic tissue. Prostate cancer is mostly androgen-dependent and can be treated with surgical or chemical castration. To date, antiandrogen monotherapy has not consistently been shown to be equivalent to castration.
Nilutamida Lafedar is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Nilutamida Lafedar is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Nilutamida Lafedar blocks the action of androgens of adrenal and testicular origin that stimulate the growth of normal and malignant prostatic tissue. Prostate cancer is mostly androgen-dependent and can be treated with surgical or chemical castration. To date, antiandrogen monotherapy has not consistently been shown to be equivalent to castration. The relative binding affinity of nilutamide at the androgen receptor is less than that of bicalutamide, but similar to that of hydroxuflutamide.
The relative binding affinity of nilutamide at the androgen receptor is less than that of bicalutamide, but similar to that of hydroxuflutamide.
| Trade Name | Nilutamida Lafedar |
| Availability | Prescription only |
| Generic | Nilutamide |
| Nilutamide Other Names | Nilutamida, Nilutamide, Nilutamidum |
| Related Drugs | estradiol, Premarin, Xtandi, Casodex, Zytiga, Lynparza |
| Type | |
| Formula | C12H10F3N3O4 |
| Weight | Average: 317.2207 Monoisotopic: 317.062340438 |
| Groups | Approved, Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | Argentina |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Nilutamida Lafedar is an antineoplastic hormone used to treat prostate cancer.
For use in combination with surgical castration for the treatment of metastatic prostate cancer involving distant lymph nodes, bone, or visceral organs (Stage D2).
Nilutamida Lafedar is also used to associated treatment for these conditions: Metastatic Hormone Refractory Prostate Cancer
How Nilutamida Lafedar works
Nilutamida Lafedar competes with androgen for the binding of androgen receptors, consequently blocking the action of androgens of adrenal and testicular origin that stimulate the growth of normal and malignant prostatic tissue. This blockade of androgen receptors may result in growth arrest or transient tumor regression through inhibition of androgen-dependent DNA and protein synthesis.
Toxicity
Symptoms of overdose include dizziness, general discomfort, headache, nausea, and vomiting.
Food Interaction
- Avoid alcohol.
- Take separate from meals. Take before breakfast.
[Moderate] GENERALLY AVOID: Alcohol intolerance has been reported in 5% to 20% of patients following administration of nilutamide in clinical studies.
Symptoms include facial flushes, malaise, and hypotension.
MANAGEMENT: Consumption of alcoholic beverages should be avoided in patients who experience alcohol intolerance with nilutamide.
Nilutamida Lafedar Drug Interaction
Moderate: doxorubicin, doxorubicinUnknown: paclitaxel protein-bound, paclitaxel protein-bound, dutasteride, dutasteride, aspirin, aspirin, bicalutamide, bicalutamide, estradiol, estradiol, rosuvastatin, rosuvastatin, leuprolide, leuprolide, apixaban, apixaban, estradiol, estradiol
Nilutamida Lafedar Disease Interaction
Elimination Route
Rapidly and completely absorbed, yielding high and persistent plasma concentrations.
Half Life
38.0-59.1 hours
Elimination Route
Nilutamida Lafedar is extensively metabolized andless than 2% of the drug is excreted unchanged in urine after 5 days. Fecal elimination is negligible, ranging from 1.4% to 7% of the dose after 4 to 5 days.
Innovators Monograph
You find simplified version here Nilutamida Lafedar
